Bank of America
VRAX icon

Bank of America’s Virax Biolabs VRAX Stock Holding History

Bank of America’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-36
Closed -$28K – 8456
2022
Q3 		$28K Buy
+36
New +$59.5K ﹤0.01% 6910

Other funds holding VRAX

KI
Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RAM
Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return

Bank of America's VRAX Position: Q4 2022 in Review

Bank of America sold out of Virax Biolabs (VRAX) in Q4 2022, closing a stake of 36 shares — an estimated $28K sold.

Bank of America first reported a position in VRAX in Q3 2022 and held it in 1 quarter. The position peaked at $28K in Q3 2022. 7 funds tracked by Wall St. Rank hold VRAX as of Q4 2022.

  • Bank of America reported no remaining Virax Biolabs position as of Q4 2022 after selling out during the quarter.
  • Bank of America sold 36 Virax Biolabs shares in Q4 2022, an estimated $28K.
  • Bank of America first reported a position in Virax Biolabs in Q3 2022 and held it in 1 quarter.
  • Bank of America's Virax Biolabs position peaked at $28K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2022.

Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.